GlassScriptPhysician profile
Joseph Heng
NPI 1700270154
$6,745.98
in general payments reported to CMS, 2019-2025
15 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.15 · 2023: $2,634 · 2024: $3,240 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,513 · Food and Beverage: $1,153 · Travel and Lodging: $65.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,512.50 |
| Food and Beverage | $1,152.67 |
| Travel and Lodging | $65.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,768.36 | 2023-2024 | Lunsumio |
| Janssen Scientific Affairs, LLC | $967.50 | 2023-2025 | Talvey |
| Janssen Biotech, INC. | $254.99 | 2023-2025 | Tecvayli, Talvey |
| Exelixis INC. | $174.91 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $140.00 | 2025 | Onivyde |
| Pfizer INC. | $67.03 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $64.90 | 2023-2024 | Clonoseq |
| Merck Sharp & Dohme LLC | $61.00 | 2022-2025 | Keytruda, Keytruda Qlex |
| Celgene Corporation | $57.64 | 2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $46.86 | 2025 | |
| Lilly USA, LLC | $45.81 | 2024-2025 | Verzenio |
| Abbvie INC. | $38.05 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.42 | 2025 | Opdivo |
| Tempus Ai, INC | $19.81 | 2024 | |
| Genmab U.S., INC. | $17.70 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Heng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.